Fatal acute liver failure with hepatitis B virus infection during natalizumab treatment in multiple sclerosis
Citation Manager Formats
Make Comment
See Comments
This article has a correction. Please see:

Article Information
- Received August 28, 2014
- Accepted in final form January 12, 2015
- First Published February 12, 2015.
Author Disclosures
- Machteld E. Hillen, MD,
- Stuart D. Cook, MD,
- Arun Samanta, MD,
- Evan Grant, MD,
- James R. Quinless, ANP and
- Jamuna K. Rajasingham, MD
- Machteld E. Hillen, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Roche (2) Biogen Idec, Inc. (3) Novartis Pharmaceuticals, Corporation
(1) NIH/NINDS, grant number 2R01NS077946, co-investigator, 10/1/12-09/30/17
NONE
(1) CDHI Foundation, Inc.
NONE
NONE
NONE
NONE
NONE
NONE
- Stuart D. Cook, MD,
(1) Bayer Healthcare (2) Merck Serono (3) Actinobac Biomed (4) Teva Pharmaceuticals (5) Biogen Idec
NONE
NONE
(1) Neurology Reviews, Editor, 1997-present
NONE
NONE
NONE
(1) Merck Serono (2)
NONE
NONE
NONE
(1) Merck Serono (2) Bayer Healthcare (3) Biogen Idec (4) Roche (5) Novartis Pharmaceuticals
NONE
NONE
(1) National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- Arun Samanta, MD,
NONE
NONE
Vertex Pharmaceuticals: Speaker honorarium Gilead Pharmaceuticals: Speaker honorarium
NONE
NONE
NONE
NONE
NONE
Vertex Pharmaceuticals: Speakers' Bureau Gilead Pharmaceuticals: Speakers' Bureau
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Evan Grant, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- James R. Quinless, ANP and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
1)Merck-Serono 2)Bayer HealthCare 3)Roche 4)Biogen 5)Novartis Pharmaceuticals
NONE
NONE
1)National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- Jamuna K. Rajasingham, MD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology and Neurosciences (M.E.H., S.D.C., J.R.Q.) and Department of Medicine (A.S.), Rutgers-NJMS, Newark, NJ; Department of Physical Medicine and Rehabilitation (E.G.), NYU Langone Medical Center, New York, NY; and Hackensack University Medical Center (J.K.R.), Hackensack, NJ.
- Correspondence to Dr. Hillen: machteld.hillen{at}rutgers.edu
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Daniel Friedman and Dr. Sharon Chiang